CDKN1B and melanoma: We have reported that miR-221 and -222 act on melanoma progression through multiple oncogenic pathways downregulating p27Kip1 and c-KIT receptors, leading to enhanced proliferation and blocking the differentiation of melanoma cells (Felicetti et al., 2008).